Drug pricing policy under the Trump administration

Later this month, Donald J. Trump will officially become the 47th President of the United States. After a plethora of health care nominations following the 2024 Presidential Election, questions about how this second Trump administration will approach health care policy have risen. Sheila P. Burke explains what the Trump administration's approach to drug pricing policy might look like, and what implications this could have on the greater health care landscape.

Sheila P. Burke served for 19 years on Capitol Hill, notably serving as Deputy Chief of Staff and later Chief of Staff to Senate Majority Leader Bob Dole, where she was involved in legislation related to Medicare, Medicaid and the Maternal and Child Health programs, among others. She was elected Secretary of the Senate in 1995, and served as a member of the Medicare Payment Advisory Commission (MedPAC) from 2000-2007.